摘要
The aim of this study was to investigate the expression of macrophage migration inhibitory factor （MMIF）, hypoxia-inducible factor- 1 α（HIF- 1α ）and vascular endothelial growth factor （VEGF） in the serum and endometrial tissues of patients with endometriosis （EM） and the clinical significance. Eighty EM patients [American Reproductive Association stage Ⅰ （n=20）, stage Ⅱ （n=22）, stage Ⅲ （n=21） and stage Ⅳ （n=17）] were enrolled and divided into mild （10- 14 points, n=28）, moderate （16-24 points, n=27） and severe （26-30 points, n=25） dysmenorrhea groups. The control group included 40 healthy women of childbearing age who underwent routine healthcare examinations in the enrolment period. The expression of MMIF, HIF- 1α and VEGF in the serum and endometrial tissues was measured by enzyme-linked immunosorbent assay and Western blotting, respectively. Meanwhile, the sensitivity and specificity of serum MMIF, HIF-1α, and VEGF when separately used as single indexes or jointly used as one index were examined as well. The results showed that serum concentrations of MMIF, HIF-1α, and VEGF were significantly higher in EM patients than in controls （P〈0.05）. The expression of all three proteins in both serum and endometrial tissues increased significantly with the R-AFS stage （P〈0.05） and with dysmenorrheal severity （P〈0.05）. The sensitivity and specificity of the combined detection of serum MMIF, HIF-1α, and VEGF levels were significantly higher than those of single index detection （P〈0.05）. In conclusion, the expression of MMIF, HIF-1α, and VEGF in the serum and endometrial tissues may be used to assess the stage of EM and the severity of dysmenorrhea. Combined evaluation of MMIF, HIF-1α, and VEGF significantly improves the diagnostic sensitivity and specificity.
The aim of this study was to investigate the expression of macrophage migration inhibitory factor （MMIF）, hypoxia-inducible factor- 1 α（HIF- 1α ）and vascular endothelial growth factor （VEGF） in the serum and endometrial tissues of patients with endometriosis （EM） and the clinical significance. Eighty EM patients [American Reproductive Association stage Ⅰ （n=20）, stage Ⅱ （n=22）, stage Ⅲ （n=21） and stage Ⅳ （n=17）] were enrolled and divided into mild （10- 14 points, n=28）, moderate （16-24 points, n=27） and severe （26-30 points, n=25） dysmenorrhea groups. The control group included 40 healthy women of childbearing age who underwent routine healthcare examinations in the enrolment period. The expression of MMIF, HIF- 1α and VEGF in the serum and endometrial tissues was measured by enzyme-linked immunosorbent assay and Western blotting, respectively. Meanwhile, the sensitivity and specificity of serum MMIF, HIF-1α, and VEGF when separately used as single indexes or jointly used as one index were examined as well. The results showed that serum concentrations of MMIF, HIF-1α, and VEGF were significantly higher in EM patients than in controls （P〈0.05）. The expression of all three proteins in both serum and endometrial tissues increased significantly with the R-AFS stage （P〈0.05） and with dysmenorrheal severity （P〈0.05）. The sensitivity and specificity of the combined detection of serum MMIF, HIF-1α, and VEGF levels were significantly higher than those of single index detection （P〈0.05）. In conclusion, the expression of MMIF, HIF-1α, and VEGF in the serum and endometrial tissues may be used to assess the stage of EM and the severity of dysmenorrhea. Combined evaluation of MMIF, HIF-1α, and VEGF significantly improves the diagnostic sensitivity and specificity.
